An Introduction to Atrial Fibrillation
In recent years the management of patients with atrial fibrillation (AF) has made good progress, however it still remains one of the major causes of stroke, heart failure, sudden death, and cardiovascular morbidity globally. Community awareness of arrhythmias and detection are important to allow early diagnosis and treatment to avoid stroke and other complications.
Browse the content below where leading experts discuss the latest data in video interviews and short articles from our conference hub, and browse the selection of peer- reviewed articles from our journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Atrial Fibrillation Content
Pathogenesis of Atrial Fibrillation in Patients with Diabetes Mellitus: Impact on Ablation and Disease Recurrence
European Journal of Arrhythmia & Electrophysiology. 2021;7(1):26-32 DOI: https://doi.org/10.17925/EJAE.2021.7.1.26
Atrial fibrillation (AF) is the most common cardiac arrhythmia observed in clinical practice worldwide.1 The incidence of AF is around 0.1% in individuals under 55 years old and 9% in those aged over 80.2 The global prevalence of AF is estimated to be around 44 million, which is approximately 0.5% of the total world population.3,4 Therefore, […]
Management of Atrial Fibrillation in Recipients of Cardiac Resynchronization Therapy
European Journal of Arrhythmia & Electrophysiology. 2021;7(1):19-25 DOI: https://doi.org/10.17925/EJAE.2021.7.1.19
Atrial fibrillation (AF) and heart failure (HF) often co-exist. The incidence of AF is estimated to reach 45% of patients with HF and rises with the severity of HF symptoms, from about 5% of patients in the New York Heart Association (NYHA) class I to 50% in NYHA class IV.1–4 Consistently, the incidence of AF […]
Anthony Tang, ACC 2021: Findings from the RAFT-AF Trial
It was a great pleasure to meet with Anthony Tang to discuss the RAFT-AF trial results investigating the safety and efficacy of catheter ablation-based rhythm control compared with rate control for the treatment of patients with atrial fibrillation and heart failure, presented at ACC 2021. Abstract Title: A Randomized Ablation-based atrial Fibrillation rhythm control versus […]
Michiel Rienstra and Bao-Oanh Nguyen, EHRA 2021 – Long-term Outcomes of the RACE 3 Trial
Professor Michiel Rienstra and Dr Bao-Oanh Nguyen (University Medical Center Groningen, Groningen, The Netherlands) gave us an overview of the RACE-3 study (NCT00877643) from the European Heart Rhythm Association (EHRA) Virtual Meeting 2021. Questions: What is the rationale for targeted therapy of underlying conditions in patients with persistent atrial fibrillation (AF) and mild to moderate […]
Faizel Osman, A-A Heart Rhythm Updates 2021: 2020 ESC AF Guidelines
We spoke to Professor Faizel Osman (Consultant Cardiologist and Electrophysiologist, University Hospital Coventry and Warwickshire NHS Trust, Coventry, UK) who gave us an update about the recent new ESC Guidelines for Atrial Fibrillation and the upcoming Arrhythmia Alliance Heart Rhythm Updates 2021. Questions What are the most important new recommendations in the 2020 ESC atrial […]
Suneet Mittal, AF Symposium 2021: Atrial Fibrillation in the Post-COVID-19 Environment
We spoke to Dr Suneet Mittal (Director of Electrophysiology, The Valley Hospital, Ridgewood, NJ, USA) about the workflow innovations for atrial fibrillation ablation in the post-COVID-19 environment. Questions What have been the main challenges to atrial fibrillation (AF) ablation workflow during the COVID-19 pandemic? (0.14) What workflow innovations have been created and incorporated over the […]
Hugh Calkins, AF Symposium 2021: the STOP Persistent AF Clinical Trial
We spoke to Professor Hugh Calkins (Johns Hopkins Hospital, Baltimore, MD, USA) about the STOP Persistent AF Clinical Trial (NCT03012841). Questions: Could you tell us a little about the aims and design of the STOP Persistent AF clinical trial? (0.13) What were the findings of the study? (0.43) What are their implications for clinical practice? […]
Hugh Calkins, AF Symposium 2021: Atrial Fibrillation and HFrEF and HFpEF
We spoke to Professor Hugh Calkins (Johns Hopkins Hospital, Baltimore, MD, USA) about atrial fibrillation and heart failure with reduced and preserved ejection fraction. Questions: What is the prevalence of atrial fibrillation (AF) in patients with heart failure (HF) and reduced (HFrEF) and preserved (HFpEF) ejection fraction? (0.13) What is the impact of AF on […]
David Keane, AF Symposium 2021: Challenges in Catheter Ablation
We spoke to Professor David Keane (St Vincent’s University Hospital, Dublin, Ireland) about the current challenges procedural duration and overall success in catheter ablation, and the most exciting innovations to aim to overcome these. Questions: What are the current challenges in catheter ablation in terms of procedural duration and overall success? (0.13) What are the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!